Generic Name and Formulations:
Besifloxacin 0.6%; oph susp; contains benzalkonium chloride.
Bausch & Lomb Inc.
Indications for BESIVANCE:
Susceptible bacterial conjunctivitis.
Adults and Children:
<1yr: not established. ≥1yr: 1 drop in affected eye(s) 3 times daily (4–12hrs apart) for 7 days. Shake bottle once before use.
Not for inj into the eye. Avoid contact lenses during therapy or if symptomatic. Pregnancy. Nursing mothers.
Conjunctival redness, blurred vision, eye pain/pruritus/irritation, headache; superinfection (discontinue and treat).
Endocrinology Advisor Articles
- Relationship Between HbA1c and Coronary Artery Disease
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Weight Gain After Quitting Smoking May Increase Risk for T2D
- In Teens, Young Adults, High BMI May Hurt Cardiovascular Health
- Obesity Paradox Affects Type 2 Diabetes Mortality Rates
- Bi-Directional Association Observed Between Obstructive Sleep Apnea and Diabetes
- Real-World Data Show Reduced Fracture Rates in Teriparatide-Treated Osteoporosis